Impaired immune functions leading to primary immunodeficiencies often correlate with paradoxical autoimmune complications; patients with hyper-IgM syndromes who are deficient in activationinduced cytidine deaminase (AID), which is required for classswitch recombination and somatic hypermutation, are prone to develop autoimmune diseases. To investigate the impact of AIDdeficiency on early B-cell tolerance checkpoints in humans, we tested by ELISA the reactivity of recombinant antibodies isolated from single B cells from AID-deficient patients. New emigrant/ transitional and mature naive B cells from AID-deficient patients express an abnormal Ig repertoire and high frequencies of autoreactive antibodies, demonstrating that AID is required for the establishment of both central and peripheral B-cell tolerance. In addition, B-cell tolerance was further breached in AID-deficient patients as illustrated by the detection of anti-nuclear IgM antibodies in the serum of all patients. Thus, we identified a major and previously unsuspected role for AID in the removal of developing autoreactive B cells in humans.
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H
yper IgM (HIGM) syndromes are primary immunodeficiencies characterized by defects in class switch recombination (CSR), resulting in severely decreased numbers of circulating isotype-switched memory B cells (1) . The genetic basis of HIGM is diverse and is caused by defects in (i) the CD40L/ CD40 pathway essential for B-cell activation, germinal center (GC) formation, and CSR induction, or (ii) enzymes such as activation-induced cytidine deaminase (AID) and uracil DNA glycosylase mediating CSR and somatic hypermutation (2) (3) (4) (5) . Aside from the susceptibility to bacterial infections, patients with HIGM syndromes are prone to develop autoimmune conditions, suggesting that B-cell tolerance is not properly established or maintained in the absence of functional CD40L or AID (6, 7) . Although developing autoreactive B cells are properly counterselected in the bone marrow of CD40L-deficient patients, their mature naive B cells express a high proportion of autoreactive antibodies, including antinuclear antibodies (ANAs), suggesting that CD40/CD40L interactions are essential for peripheral but not central B-cell tolerance in humans (8) . The defective peripheral B-cell tolerance checkpoint in CD40L-deficient patients correlated with decreased regulatory T cell (Treg) numbers and elevated serum B-cell activating factor (BAFF) concentration, corroborating data from transgenic mouse models (8) (9) (10) (11) . The importance of Treg cells in the establishment or the maintenance of peripheral tolerance is demonstrated in foxp3-deficient mice and humans, who experience a severe autoimmune syndrome associated with the secretion of autoreactive antibodies (12) (13) (14) . In addition, increased BAFF concentration inhibits the counterselection of autoreactive new emigrant/transitional B cells that failed to be removed from the B-cell population (15, 16) . Hence, the elevated serum BAFF concentration and decreased Treg cell numbers in CD40L-deficient patients are likely to contribute to the accumulation of autoreactive mature naive B cells in the blood of these patients (8) .
In contrast to CD40L-deficient patients, it is not known why AID-deficient subjects as well as AID-KO mice often suffer from autoimmune conditions (6, 17, 18) . We report herein that AID deficiency affects both central and peripheral B-cell tolerance checkpoints, resulting in the accumulation of large numbers of autoreactive B cells that secrete autoreactive IgM antibodies detected in the serum of all AID-deficient patients.
Results
Defective Central B-Cell Tolerance in AID-Deficient Patients. Central B-cell tolerance is achieved by the removal of most developing B cells that express highly polyreactive and ANAs in the bone marrow (19 
CD27
− new emigrant/transitional B cells from AIDdeficient patients (SI Appendix, Table S1 ) and tested their reactivity by ELISA (20) . Patients were either homozygote or compound heterozygote for autosomal recessive AID mutations, preventing AID expression in most cases (21) . The first evidence suggesting that central B-cell tolerance was not established properly in the absence of AID expression came from the analysis of the Ig repertoire of new emigrant/transitional B cells from seven AID-deficient patients (SI Appendix, Table S1 ). Pooled heavy-chain gene sequences from AID-deficient new emigrant/transitional B cells revealed a VH repertoire strongly enriched in the VH4-34 gene segment compared with that of healthy donors (Fig. 1A) . The frequency of VH4-34, which is known to encode intrinsically self-reactive cold agglutinin antibodies that recognize carbohydrate antigens on erythrocytes (22, 23) , exceeded 20% in some AID-deficient patients, but averaged only 4.2% in transitional B cells from healthy donors (P = 0.0093; Fig. 1B) , suggesting an abnormal selection of developing B-cell precursors in the absence of AID. New emigrant/transitional B cells from AID-deficient patients also displayed a significantly higher frequency of long IgH complementarity determining regions 3 (CDR3s), a feature that favors antibody self-reactivity (Fig. 1C) (20, 24) . However, the frequency of strongly positively charged IgH CDR3s, a feature also associated with autoreactive antibodies, was not significantly different between healthy donor and AID-deficient new emigrant/transitional B cells (Fig. 1D) . Moreover, despite a similar D and JH gene segment repertoire in control and AID-deficient new emigrant/transitional B cells (SI Appendix, Fig. S1 and Tables S2-S25), we found that some commonly used D gene family members were used in a different reading frame in AID-deficient patients, which encoded hydrophobic residues known to favor self-reactivity (SI Appendix, Fig. S2 ) (25) (26) (27) .
The reactivities of antibodies expressed by new emigrant/ transitional B cells from four AID-deficient patients were then compared with their counterparts in healthy donor controls and CD40L-deficient patients with HIGM syndrome (Fig. 2 A-C) (8, 20, 27, 28) . We found that polyreactive new emigrant/transitional B cells were significantly increased in AID-deficient patients (25.0-42.1% of the clones) compared with healthy controls (5.0-11.1%) or CD40L-deficient patients (4.3-9.5%; Fig. 2 A and B) (8, 20, 27, 28) . Antibodies from AID-deficient new emigrant/ transitional B cells predominantly recognized cytoplasmic structures, and only two of 70 clones, neAID-def.4 λ41 and neAIDdef.5 κ03, bound nuclear antigens ( Fig. 2 C and D) , suggesting that the early counterselection of antinuclear expressing B cells, which requires IRAK-4 and MyD88 (29) may not be AIDdependent. Thus, the abnormal Ig repertoires and the increased frequency of polyreactive clones in new emigrant B cells from AID-deficient patients demonstrate that central B-cell tolerance is dependent on functional AID.
AID Gene Transcription in Human Immature B Cells. The analysis of patients with diverse primary immunodeficiencies revealed that central tolerance seems to be mostly controlled by B-cellintrinsic factors regulating B-cell receptor or Toll-like receptor (TLR) signaling (27, 29) . Although AID expression was previously believed to be restricted to activated B cells and GCs, it has now been observed in immature B cells from mice and humans, pointing to an earlier role for AID during bone marrow B-cell development (30) (31) (32) (33) . In agreement with these reports, we detected AID transcripts by quantitative PCR in CD19 
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− early B-cell precursors, whereas AID transcripts were not amplified in more mature B-cell fractions isolated from fetal spleen or tonsils ( active mature naive B cells was significantly increased (44.4-57.1%) in AID-deficient patients compared with healthy donors (16.7-23.3%) and was similar to that previously reported for CD40L-deficient patients (Fig. 4C ) (8) . AID-deficient mature naive B cells were also enriched in polyreactive clones compared with healthy controls (Fig. 4D ). In agreement with the enrichment of clones expressing highly positively charged IgH CDR3s, we found an increased proportion of mature naive B cells expressing ANAs in all AID-deficient patients, further suggesting the existence of selection defects between transitional and mature naive B cells (Fig. 4 E and  F) . Indeed, whereas ANA-expressing B cells were almost absent in AID-deficient new emigrant B cells, their frequency significantly increased to 7.1-14.3% (total of eight of 73 clones) in the mature naive B-cell compartment (Fig. 4F) . ANAs expressed by AID-deficient mature naive B cells displayed diverse nuclear staining patterns and the presence of chromatin-reactive antibodies was confirmed by the identification of clones recognizing the kinetoplast of Crithidia luciliae (Fig. 4 E and G) . We conclude that the absence of functional AID alters the peripheral B-cell tolerance checkpoint and results in the accumulation in the mature naive B-cell compartment of large numbers of B cells expressing autoreactive antibodies including ANAs in AID-deficient patients.
Decreased Treg Cell Frequencies and Increased Serum BAFF Concentrations in AID-Deficient Patients. The emergence of ANAexpressing B cells was previously observed in CD40L-deficient patients and correlated with decreased Treg frequencies and increased concentrations of serum BAFF (8) . We found that CD4 + CD25 hi Foxp3 + Treg cell frequency was significantly decreased in AID-deficient patients, who displayed, on average, approximately half the Treg cells as healthy controls (Fig. 5 A-C) . The phenotype of the AID-deficient and control Treg cells was further confirmed by low levels of IL-7 receptor/CD127 expression on CD4 + CD25 hi Foxp3 + cells (Fig. 5B) (34, 35) . This decreased Treg cell frequency in CD40L-and AID-deficient patients might reveal an involvement of isotype switched memory B cells missing in both types of HIGM patients in the generation or maintenance of some Treg cells in humans. The impact of B cells on Treg cells is further suggested in patients with X-linked agammaglobulinemia (XLA), who virtually lack B cells (36) and display decreased frequencies of Treg cells (Fig. 5C and SI Appendix, Fig. S5 ). Serum BAFF concentrations were significantly (twofold) increased in AID-deficient patients, averaging 2,272 pg/ mL compared with 1,226 pg/mL in healthy donors (P < 0.0001) and 4,009 pg/mL and 11,739 pg/mL in CD40L-deficient patients and those with XLA, respectively (Fig. 5D) . The increased concentrations of BAFF in patients with XLA likely result from the virtual absence of B cells in these patients. However, it is unclear how AID and CD40L deficiencies impact serum BAFF concentrations because AID-and CD40L-deficient patients display normal numbers of B cells in their blood. Nevertheless, increased BAFF concentrations in AID-deficient patients are likely to interfere with the counterselection of autoreactive transitional B cells, as evidenced in mouse models (15, 16) . Hence, decreased Treg cell frequencies and increased serum BAFF concentrations correlate with an altered peripheral B-cell tolerance checkpoint in both AID-and CD40L-deficient patients.
AID-Deficient Patients Display Serum IgM ANAs. We assessed whether tolerance was further breached in the periphery of AIDdeficient patients by analyzing their sera for autoreactive antibodies. We found that eight of eight AID-deficient patients displayed autoreactive antibodies in their serum. These antibodies recognized many HEp-2 cell structures and the kinetoplast of C. luciliae, indicating the presence of anti-dsDNA autoantibodies in AID-deficient patients (Fig. 5E ). Staining specificity was restricted to IgM antibodies and no IgG autoreactive antibodies were identified as expected for AID-deficient patients (Fig. 5E) . A similar HEp-2 staining pattern was observed for IgM autoantibodies in the serum of a patient with systemic lupus erythematosus, whereas the IgG staining pattern was clearly nuclear. In contrast, none of five CD40L-deficient patients and six healthy donors we tested displayed any antibodies that recognized HEp-2 cells or C. luciliae in their serum (Fig. 5E) . We conclude that B-cell tolerance is further breached in AID-deficient patients compared with CD40L-deficient patients, leading to the secretion of autoreactive antibodies including anti-dsDNA in the serum of all AID-deficient patients.
Discussion
The identification of defective central and peripheral B-cell tolerance checkpoints in AID-deficient patients demonstrates an important role for AID expression in the removal of developing autoreactive B cells. The mechanisms by which AID affects central B-cell tolerance are currently unknown, but because the mechanisms that ensure human central B-cell tolerance seem to be mostly controlled by intrinsic B-cell factors, AID expression in immature B cells might be relevant to tolerance induction (19, 37, 38) . For instance, AID might induce DNA lesions that eventually lead to cell death and the elimination of autoreactive clones; AID-deficient B cells may therefore be less sensitive to apoptosis, a mechanism involved in central B-cell tolerance, as recently reported in mice (39) . AID deamination of methylated cytidines might also induce DNA demethylation potentially required for the epigenetic regulation of gene expression [and perhaps V(D)J recombination and receptor editing (40)]. AID expression was previously believed to be restricted to GCs, but it has now been reported in ES cells (41, 42) as well as in immature B cells from mice and humans (30) (31) (32) (33) , suggesting an earlier role for AID during bone marrow B-cell development. We also detected AID transcripts in human immature B cells, but 20 to 25 times lower than in GC B cells. Although AID transcription may be upregulated in immature B cells after TLR9 triggering, these low AID transcript levels may not be relevant to immature B-cell physiology and the removal of developing autoreactive B cells. Alternatively, early B-cell tolerance alteration observed in AID-deficient patients may not result from intrinsic B-cell defects but perhaps from a failure to control intestinal microflora (43) . Indeed, intestinal inflammation and microflora changes may result in the alteration of Treg cell frequencies and serum BAFF concentrations in AID-deficient patients, thereby inducing peripheral Bcell tolerance defects similar to those reported in CD40L-deficient patients (8, 43, 44) . Moreover, the lack of isotype-switched memory B cells in patients with both types of HIGM and XLA might also contribute to Treg cell alterations because B cells have been reported to be involved in T-cell activation and expansion (45) (46) (47) . Treg cell frequencies were further decreased in CD40L-deficient patients compared with AID-deficient patients, probably because disruption of CD40/CD40L interactions between Treg cells and APCs such as dendritic cells, which are known to control Treg cell development (48) , contributes to an even more pronounced defect in the induction or maintenance of Treg cells. Although both CD40L-and AID-deficient patients display high frequencies of autoreactive mature naive B cells, including ANA-expressing clones in their blood, an additional breach in B-cell tolerance is revealed in AID-deficient patients by the detection of ANAs and autoreactive IgM antibodies in their serum, which may favor the development of autoimmune disorders in these patients. It also demonstrates that ANA clone production and secretion can occur in the absence of somatic hypermutation despite its documented importance in the production of ANAs (49, 50) . Interestingly, AID-deficient animals display B-cell tolerance defects similar to those reported herein, further attesting a conserved role for AID during early B-cell development in mice and humans (51) . In conclusion, AID plays a major and previously unsuspected role in the establishment of both central and peripheral B-cell tolerance.
Materials and Methods
Patients and Donor Controls. AID-deficient patients' information is included in SI Appendix, Table S1 . CD40L-deficient and XLA patients, as well as agematched healthy donors, were previously reported besides HD12 (29-y-old white female), HD13 (31-y-old white male), HD14 (59-y-old white male), HD15 (53-y-old Hispanic female), and CD40L-deficient patients 8 and 9, who are two Hispanic brothers 11 and 14 y of age, respectively, who have an entire deletion of their CD40L gene (8, 20, (27) (28) (29) 52 and control donors were sorted on a FACSVantage device (Becton Dickinson) into 96-well PCR plates, and antibody reactivities were tested as previously described (8, 20, (27) (28) (29) 52 ). For Treg cell analyses, peripheral mononuclear blood cells were stained with FITC anti-CD4, PECy7 anti-CD25, and APC-anti-CD127 (Biologend), and intracellular Foxp3 stainings were performed according to the manufacturer's instructions (eBioscience). Serum BAFF concentrations were determined by ELISA according to the manufacturer's instruction (R&D Systems). − mature naive B cells were also isolated from the spleen of the same fetuses by using a similar approach. Total RNA was extracted from B cells using the Absolutely RNA MicroPrep kit (Stratagene), followed by cDNA synthesis with SuperScript II RT (Gibco BRL .
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